相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。1248PA PHASE IB OPEN LABEL CLINICAL TRIAL OF CONTINUOUS ONCE DAILY ORAL AFATINIB (A) PLUS SIROLIMUS (S) IN PATIENTS (PTS) WITH EGFR MUTATION POSITIVE (EGFR M+) NSCLC AND/OR DISEASE PROGRESSION FOLLOWING PRIOR ERLOTINIB (E) OR GEFITINIB (G)
T. Moran et al.
ANNALS OF ONCOLOGY (2017)
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
M. Schuler et al.
ANNALS OF ONCOLOGY (2016)
Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases
Hideko Isozaki et al.
CANCER RESEARCH (2016)
AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective
Samuel H. Myers et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Activation of EGFR Bypass Signaling by TGF alpha Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells
Tetsuo Tani et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study
Naoko Sueoka-Aragane et al.
CANCER SCIENCE (2016)
Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure
Takahisa Kawamura et al.
CANCER SCIENCE (2016)
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
Yoshihisa Kobayashi et al.
CANCER SCIENCE (2016)
Melanoma Risk and Citrus Consumption Reply
Shaowei Wu et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014
Benjamin J. Solomon et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2
Lucio Crino et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Scott Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer
Shuhang Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls
Daniel Shao-Weng Tan et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study
Pasi A. Janne et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results
J. Yang et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib
Shiro Fujita et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK plus ) non-small cell lung cancer (NSCLC) in a phase 1/2 trial
R. Rosell et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose
K. Park et al.
Journal of Thoracic Oncology (2016)
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
Dong-Wan Kim et al.
LANCET ONCOLOGY (2016)
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
Alice T. Shaw et al.
LANCET ONCOLOGY (2016)
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Keunchil Park et al.
LANCET ONCOLOGY (2016)
K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature
Maria Cecilia Mengoli et al.
LUNG CANCER (2016)
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Yong Jia et al.
NATURE (2016)
Update to Rociletinib Data with the RECIST Confirmed Response Rate
Lecia V. Sequist et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation
Chaolun An et al.
PATHOLOGY & ONCOLOGY RESEARCH (2016)
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
Jacob J. Chabon et al.
NATURE COMMUNICATIONS (2016)
Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing
Ying Jin et al.
ONCOTARGET (2016)
Study of efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanced non-small cell lung cancer patients with secondary drug resistance: A single center, single arm, phase II clinical trial
Yanzhe Zhu et al.
THORACIC CANCER (2016)
Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is especially beneficial to patients with exon 19 deletion compared with exon 21 L858R mutation in non-small-cell lung cancer: Systematic review and meta analysis
Yinghui Liu et al.
THORACIC CANCER (2016)
Circulating tumour DNA and resistance mechanisms during EGFR inhibitor therapy in lung cancer
Carles Escriu et al.
JOURNAL OF THORACIC DISEASE (2016)
Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells
Xuyuan Dong et al.
NEOPLASIA (2016)
Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
D. Zheng et al.
SCIENTIFIC REPORTS (2016)
Tackling ALK in non-small cell lung cancer: the role of novel inhibitors
Francesco Facchinetti et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2016)
Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?
Paola Ulivi
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
H. Yoshioka et al.
ANNALS OF ONCOLOGY (2015)
A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer
Frederick H. Wilson et al.
CANCER CELL (2015)
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
Helen Y. Zou et al.
CANCER CELL (2015)
Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib
Primo N. Lara et al.
CLINICAL CANCER RESEARCH (2015)
A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial
R. A. Stahel et al.
EUROPEAN JOURNAL OF CANCER (2015)
Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors
M. G. Dal Bello et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Randomized Phase II Study of Carboplatin and Paclitaxel With Either Linifanib or Placebo for Advanced Nonsquamous Non-Small-Cell Lung Cancer
Suresh S. Ramalingam et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
KRAS tests utilizations, biologics uptakes, and disparities in access by demographic groups among metastatic colon cancer patients
Daisuke Goto et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Is C-Reactive Protein a Specific Marker in Melanoma?
Zhi Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Giorgio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer Results from the Phase II BASALT-1 Study
Johan F. Vansteenkiste et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma
Simona Coco et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
James C-H Yang et al.
LANCET ONCOLOGY (2015)
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer
Gorjan Hrustanovic et al.
NATURE MEDICINE (2015)
Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer
L. V. Sequist et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2)
Anita Kort et al.
PHARMACOLOGICAL RESEARCH (2015)
Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data
Gouji Toyokawa et al.
ONCOLOGY RESEARCH AND TREATMENT (2015)
Mechanisms of resistance to EGFR tyrosine kinase inhibitors
Lihua Huang et al.
ACTA PHARMACEUTICA SINICA B (2015)
Alectinib: A Review of Its Use in Advanced ALK-Rearranged Non-Small Cell Lung Cancer
Kate McKeage
DRUGS (2015)
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition
Simona Coco et al.
TARGETED ONCOLOGY (2015)
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib
Karen L. Reckamp et al.
CANCER (2014)
Afatinib for the treatment of advanced non-small-cell lung cancer
Carlo Genova et al.
EXPERT OPINION ON PHARMACOTHERAPY (2014)
Updated Data of a Phase 1/2 Study (AF-001JP) of Alectinib, a CNS-Penetrant, Highly Selective ALK Inhibitor in ALK-rearranged Advanced NSCLC
T. Tamura et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Use of Statins and the Risk of Death in Patients With Prostate Cancer
Oriana Yu et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
Ted W. Johnson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
Shirish M. Gadgeel et al.
LANCET ONCOLOGY (2014)
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
Takashi Seto et al.
LANCET ONCOLOGY (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer REPLY
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
Adam S. Crystal et al.
SCIENCE (2014)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations
Yelena Y. Janjigian et al.
CANCER DISCOVERY (2014)
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
Luc Friboulet et al.
CANCER DISCOVERY (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Lauren Averett Byers et al.
CLINICAL CANCER RESEARCH (2013)
Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
Justin F. Gainor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both
Nobuyuki Katakami et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials
Thomas H. Marsilje et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma Molecular Analysis of 25 ALK-Positive Cases
Jennifer M. Boland et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study
Takashi Seto et al.
LANCET ONCOLOGY (2013)
AP26113 is a dual ALK/EGFR inhibitor: Characterization against EGFR T790M in cell and mouse models of NSCLC
Victor M. Rivera et al.
CANCER RESEARCH (2012)
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
Robert C. Doebele et al.
CLINICAL CANCER RESEARCH (2012)
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Vincent A. Miller et al.
LANCET ONCOLOGY (2012)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang et al.
NATURE GENETICS (2012)
Treating ALK-positive lung cancer-early successes and future challenges
D. Ross Camidge et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
Kadoaki Ohashi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFRT790M Mutation
Ken Takezawa et al.
CANCER DISCOVERY (2012)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
Alexa B. Turke et al.
CANCER CELL (2010)
Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer
David Jackman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non-Small-Cell Lung Cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Wenjun Zhou et al.
NATURE (2009)
分享论文
